FreeTheAI

Entrada Therapeutics Cleared to Start Top Dose in DMD Trial

MixedMedium impact
TRDA$4.86 −11.64%

Entrada Therapeutics, Inc. (TRDA) has been cleared to begin Cohort 3 at the top dose of 18 mg/kg in its Phase 1/2 ELEVATE-44-201 study for Duchenne muscular dystrophy. An independent data monitoring committee recommended advancing to the highest dose level following earlier doses of 6 mg/kg and 12 mg/kg. Enrollment for Cohort 2 is now complete.

Advancing to the top dose indicates that lower dosing levels met required safety and pharmacokinetic thresholds. Testing higher dose exposure allows researchers to determine if increased dosing can improve therapeutic signals while maintaining acceptable safety.

Looking ahead, the company expects to report one-year open-label results for Cohort 1 by the end of 2026. Data from Cohort 2 are expected to follow in the first quarter of 2027. Shares of the company traded at $4.86, down 11.64% for the day.

Key points

  • An independent data monitoring committee cleared Entrada Therapeutics to begin Cohort 3 at an 18 mg/kg dose in its Phase 1/2 DMD trial.
  • Enrollment for Cohort 2 is complete following initial dose steps of 6 mg/kg and 12 mg/kg.
  • First-year open-label trial data from Cohort 1 are expected by the end of 2026.
  • Results from Cohort 2 are anticipated in the first quarter of 2027.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What is the latest update on Entrada Therapeutics DMD study?

Entrada Therapeutics received approval from an independent monitoring committee to start Cohort 3 at the highest dose of 18 mg/kg in its Phase 1/2 study.

When will Entrada Therapeutics release clinical trial data?

Cohort 1 one-year open-label data are expected by the end of 2026, and Cohort 2 data are expected in the first quarter of 2027.

What dose levels are being tested in the ELEVATE-44-201 trial?

The trial evaluates escalating dose steps from 6 mg/kg to 12 mg/kg, up to the top dose of 18 mg/kg.